144 related articles for article (PubMed ID: 15587773)
1. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
Llor C; Naberan K; Cots JM; Molina J; Miravitlles M
Int J Clin Pract; 2004 Oct; 58(10):937-44. PubMed ID: 15587773
[TBL] [Abstract][Full Text] [Related]
2. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Miravitlles M; Llor C; Naberan K; Cots JM; Molina J;
Respir Med; 2005 Aug; 99(8):955-65. PubMed ID: 15950136
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease.
Miravitlles M; García-Polo C; Domenech A; Villegas G; Conget F; de la Roza C
Lung; 2013 Oct; 191(5):523-30. PubMed ID: 23842641
[TBL] [Abstract][Full Text] [Related]
4. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
Wilson R; Anzueto A; Miravitlles M; Arvis P; Alder J; Haverstock D; Trajanovic M; Sethi S
Eur Respir J; 2012 Jul; 40(1):17-27. PubMed ID: 22135277
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Herath SC; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
[TBL] [Abstract][Full Text] [Related]
7. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.
Wilson R; Anzueto A; Miravitlles M; Arvis P; Faragó G; Haverstock D; Trajanovic M; Sethi S
Int J Chron Obstruct Pulmon Dis; 2011; 6():373-83. PubMed ID: 21760724
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.
Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2007; 2(3):191-204. PubMed ID: 18229559
[TBL] [Abstract][Full Text] [Related]
9. No more equivalence trials for antibiotics in exacerbations of COPD, please.
Miravitlles M; Torres A
Chest; 2004 Mar; 125(3):811-3. PubMed ID: 15006934
[No Abstract] [Full Text] [Related]
10. Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting.
Miravitlles M; Llor C
Clin Drug Investig; 2007; 27(2):95-104. PubMed ID: 17217314
[TBL] [Abstract][Full Text] [Related]
11. Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.
Anzueto A; Miravitlles M; Ewig S; Legnani D; Heldner S; Stauch K
Respir Med; 2012 Sep; 106(9):1258-67. PubMed ID: 22749710
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).
Chuchalin A; Zakharova M; Dokic D; Tokić M; Marschall HP; Petri T
BMC Pulm Med; 2013 Jan; 13():5. PubMed ID: 23343427
[TBL] [Abstract][Full Text] [Related]
13. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease].
Llor C; Naberan K; Cots JM; Molina J; Ros F; Miravitlles M;
Arch Bronconeumol; 2006 Apr; 42(4):175-82. PubMed ID: 16735014
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
17. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
Simoens S; Decramer M
Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.
Miravitlles M; Anzueto A; Ewig S; Legnani D; Stauch K
Ther Adv Respir Dis; 2009 Dec; 3(6):267-77. PubMed ID: 19880426
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
20. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
